FORMULATION AND EVALUATION OF NANOPARTICLE DRUG DELIVERY SYSTEM FOR TREATMENT OF HYPERTENSION

Authors

DOI:

https://doi.org/10.22159/ijap.2023v15i6.48971

Keywords:

Trandolapril, Solid lipid nanoparticles, Hypertension, Hot-homogenisation, Ultrasonication

Abstract

Objective: The aim of the current research is to formulate and evaluate Trandolapril loaded solid lipid nanoparticles (SLNs) for the management of high blood pressure.

Methods: SLNs were formulated using Glyceryl monostearate and poloxamer 188 by hot homogenisation and ultrasonication method. Different concentrations of lipid and surfactant were used for the preparation adopting 32 full factorial design. The prepared formulations were initially evaluated for particle size, PDI, zeta potential and entrapment efficiency to obtain the optimised formulation.

Results: The optimised formulation TF 6 reported the particle size of 212.6±5.39 nm and entrapment efficiency of 91.02±0.57%; this was further characterised for FT-IR, DSC and scanning electron microscopy. The in vitro release of drug for the prepared formulations was performed for 24 h and the optimised formulation showed better-controlled drug release compared to other formulations.

Conclusion: The pure Trandolapril solution was collated with the optimised formulation TF 6 and the result concluded that the formulation showed controlled drug release compared to pure drug. This study proves that Trandolapril SLNs can be prepared for increasing the release of drug for prolonged period.

Downloads

Download data is not yet available.

References

Carretero OA, Oparil S. Essential hypertension. Part I: definition and etiology. Circulation. 2000;101(3):329-35. doi: 10.1161/01.cir.101.3.329. PMID 10645931.

Danaei G, Ding EL, Mozaffarian D, Taylor B, Rehm J, Murray CJ. The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors. PLOS Med. 2009;6(4):e1000058. doi: 10.1371/journal.pmed.1000058, PMID 19399161.

Vasan RS, Beiser A, Seshadri S, Larson MG, Kannel WB, D’Agostino RB. Residual lifetime risk for developing hypertension in middle-aged women and men: the framingham heart study. JAMA. 2002;287(8):1003-10. doi: 10.1001/jama.287.8.1003, PMID 11866648.

Goit LN, Yang S. Treatment of hypertension: a review. Yangtze Med. 2019;03(2):101-23. doi: 10.4236/ym.2019.32011.

Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51(6):1403-19. doi: 10.1161/hypertensionaha.108.189141, PMID 18391085.

Khalil H, Zeltser R. Antihypertensive medications. InStatPearls. StatPearls Publishing; 2022.

Choudhury A, Laskar RE, Deka D, Sonowal K, Saha S, Dey BK. A review on nanoparticle: types, preparation and its characterization. Res J Pharm Technol. 2021;14(3):1815-22. doi: 10.5958/0974-360X.2021.00322.X.

Mukherjee S, Ray S, Thakur RS. Solid lipid nanoparticles: a modern formulation approach in drug delivery system. Indian J Pharm Sci. 2009;71(4):349-58. doi: 10.4103/0250-474X.57282, PMID 20502539.

Jawahar N, Meyyanathan SN, Reddy G, Sood S. ChemInform abstract: solid lipid nanoparticles for oral delivery of poorly soluble drugs. ChemInform. 2013;44(27). doi: 10.1002/chin.201327225.

Priyanka PA, Sri Rekha M, Devi AS. Review on formulation and evaluation of solid lipid nanoparticles for vaginal application. Int J Pharm Pharm Sci. 2022;14(1):1-8. doi: 10.22159/ijpps.2022v14i1.42595.

Shah J, Patel S, Bhairy S, Hirlekar R. Formulation optimization, characterization and in vitro anti-cancer activity of curcumin loaded nanostructured lipid carriers. Int J Curr Pharm Sci. 2022;14(1):31-43. doi: 10.22159/ijcpr.2022v14i1.44110, PMID 28842128.

Agrawal YO, Husain M, Patil KD, Sodgir V, Patil TS, Agnihotri VV. Verapamil hydrochloride loaded solid lipid nanoparticles: preparation, optimization, characterisation, and assessment of cardioprotective effect in experimental model of myocardial infarcted rats. Biomed Pharmacother. 2022;154:113429. doi: 10.1016/j.biopha.2022.113429, PMID 36007280.

Venishetty VK, Chede R, Komuravelli R, Adepu L, Sistla R, Diwan PV. Design and evaluation of polymer coated carvedilol loaded solid lipid nanoparticles to improve the oral bioavailability: a novel strategy to avoid intraduodenal administration. Colloids Surf B Biointerfaces. 2012;95:1-9. doi: 10.1016/j.colsurfb.2012.01.001, PMID 22463845.

Ekambaram P, Abdul HS. Formulation and evaluation of solid lipid nanoparticles of ramipril. J Young Pharm. 2011;3(3):216-20. doi: 10.4103/0975-1483.83765, PMID 21897661.

Bhalekar M, Upadhaya P, Madgulkar A. Formulation and characterization of solid lipid nanoparticles for an anti-retroviral drug Darunavir. Appl Nanosci. 2017;7(1-2):47-57. doi: 10.1007/s13204-017-0547-1.

Rehman MU, Khan MA, Khan WS, Shafique M, Khan M. Fabrication of niclosamide loaded solid lipid nanoparticles: in vitro characterization and comparative in vivo evaluation. Artif Cells Nanomed Biotechnol. 2018;46(8):1926-34. doi: 10.1080/21691401.2017.1396996, PMID 29113501.

Rajpoot K, Jain SK. Colorectal cancer-targeted delivery of oxaliplatin via folic acid-grafted solid lipid nanoparticles: preparation, optimization, and in vitro evaluation. Artif Cells Nanomed Biotechnol. 2018;46(6):1236-47. doi: 10.1080/21691401.2017.1366338, PMID 28849671.

Dudhipala N, Janga KY, Gorre T. Comparative study of nisoldipine-loaded nanostructured lipid carriers and solid lipid nanoparticles for oral delivery: preparation, characterization, permeation and pharmacokinetic evaluation. Artif Cells Nanomed Biotechnol. 2018;46(2)Suppl2:616-25. doi: 10.1080/21691401.2018.1465068, PMID 29688077.

Patil A, Madhumitha. Development and characterization of solid lipid nanoparticles containing antifungal agent for topical delivery. Int J Pharm Sci Res. 2023;14(1):292-309. doi: 10.13040/IJPSR.0975-8232.

Remya PN, Damodharan N. Formulation, development, and characterization of cilnidipine loaded solid lipid nanoparticles. Asian J Pharm Clin Res. 2018;11(9):120-5. doi: 10.22159/ajpcr.2018.v11i9.24666.

Vaidya A, Jain S, Jain A, Jain A. Simvastatin-loaded pegylated solid lipid nanoparticles: lipid functionalization to improve blood circulation. BioNanoScience. 2020;10(3):773-82. doi: 10.1007/s12668-020-00770-w.

Kushwaha AK, Vuddanda PR, Karunanidhi P, Singh SK, Singh S. Development and evaluation of solid lipid nanoparticles of raloxifene hydrochloride for enhanced bioavailability. BioMed Res Int. 2013;2013:584549. doi: 10.1155/2013/584549, PMID 24228255.

Shaveta S, Singh J, Afzal M, Kaur R, Imam SS, Alruwaili NK. Development of solid lipid nanoparticle as carrier of pioglitazone for amplification of oral efficacy: formulation design optimization, in vitro characterization and in vivo biological evaluation. J Drug Deliv Sci Technol. 2020;57. doi: 10.1016/j.jddst.2020.101674.

Imran B, ud Din F, Ali Z, Fatima A, Khan MW, Kim DW, Malik M, Sohail S, Batool S, Jawad M, Shabbir K. Statistically designed dexibuprofen loaded solid lipid nanoparticles for enhanced oral bioavailability. Journal of Drug Delivery Science and Technology. 2022;77:103904. doi: 10.1016/j.jddst.2022.103904.

El-Assal MI, Samuel D. Optimization of rivastigmine chitosan nanoparticles for neurodegenerative alzheimer; in vitro and ex vivo characterizations. Int J Pharm Pharm Sci. 2022;14(1):17-27. doi: 10.22159/ijpps.2022v14i1.43145, PMID 34771817.

Elbahwy IA, Ibrahim HM, Ismael HR, Kasem AA. Enhancing bioavailability and controlling the release of glibenclamide from optimized solid lipid nanoparticles. J Drug Deliv Sci Technol. 2017;38:78-89. doi: 10.1016/j.jddst.2017.02.001.

Wang T, Ma X, Lei Y, Luo Y. Solid lipid nanoparticles coated with cross-linked polymeric double layer for oral delivery of curcumin. Colloids Surf B Biointerfaces. 2016;148:1-11. doi: 10.1016/j.colsurfb.2016.08.047, PMID 27588376.

Nagaraj B, Tirumalesh C, Dinesh S, Narendar D. Zotepine loaded lipid nanoparticles for oral delivery: development, characterization, and in vivo pharmacokinetic studies. Futur J Pharm Sci. 2020;6(1):1. doi: 10.1186/s43094-020-00051-z.

Published

07-11-2023

How to Cite

U., G., PATIL, A., & G., H. (2023). FORMULATION AND EVALUATION OF NANOPARTICLE DRUG DELIVERY SYSTEM FOR TREATMENT OF HYPERTENSION. International Journal of Applied Pharmaceutics, 15(6), 90–97. https://doi.org/10.22159/ijap.2023v15i6.48971

Issue

Section

Original Article(s)